Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer
Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.
Dr. Schenk on the Evolving Treatment Landscape in Lung Cancer
Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512